{"id":"W4415390112","doi":"10.1016/j.annonc.2025.10.019","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Daiichi Sankyo Europe; Allergan; Genentech; Servier; Astellas Pharma; Seagen; Eisai; Jazz Pharmaceuticals; Taiho Pharmaceutical; Gilead Sciences; Relay Therapeutics; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Les Laboratories Pierre Fabre; Nipro","keywords":"Pertuzumab; Trastuzumab; Neoadjuvant therapy; Breast cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002040039,0.0006327159,0.002653292,0.0003923192,0.0003805885,0.0001076213,0.0006338826,0.0005385898,0.0004645977],"category_scores_gemma":[0.001504728,0.0005115619,0.0002485481,0.0006776921,0.0007286714,0.0002765224,0.0003043657,0.0007395991,0.000008281486],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007241469,"about_ca_system_score_gemma":0.004325539,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01412179,"about_ca_topic_score_gemma":0.002107448,"domain_scores_codex":[0.9944094,0.0008812856,0.001572164,0.001192984,0.0006301845,0.001313968],"domain_scores_gemma":[0.9937568,0.003077026,0.0006902111,0.0006389237,0.00114954,0.0006874501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5913251,0.006463279,0.0003430808,0.0002440223,0.001397202,0.0001570737,0.001028046,0.000001839862,0.00386734,0.00006057518,0.05092869,0.3441837],"study_design_scores_gemma":[0.921726,0.04816916,0.002107077,0.0009365706,0.001446877,0.0001720085,0.000924173,0.0004297248,0.006339619,0.0002640444,0.01690388,0.0005807981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9558613,0.003569138,0.0007778614,0.02056954,0.0006770839,0.01354884,0.003893017,0.00007922802,0.00102399],"genre_scores_gemma":[0.9854166,0.00362243,0.001517951,0.002347425,0.0003911177,0.003072449,0.0001929282,0.0001087013,0.003330422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3436029,"threshold_uncertainty_score":0.9997336,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08287070357006318,"score_gpt":0.4633421922553893,"score_spread":0.3804714886853261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}